| answer text |
<p>The National Institute for Health and Care Excellence (NICE) is the independent
body responsible for developing evidence-based guidance for the National Health Service
on whether new medicines represent a clinically and cost-effective use of resources.
The NHS in England is legally required to fund medicines recommended by NICE, usually
within three months of final guidance.</p><p>NICE published guidance in May 2022 recommending
romosozumab for treating severe osteoporosis in people after menopause who are at
high risk of fracture. Romosozumab is therefore available for clinicians to prescribe
to NHS patients who meet the specified criteria, in line with NICE’s recommendations.</p>
|
 |
